A shift towards value-based healthcare (VBC) has prompted industry participants to collaborate on innovative approaches to deliver improved outcomes in a more cost-effective manner. To reset perceptions and realize opportunities in VBC, manufacturers need to be proactive, establishing programs and partnerships that demonstrate outcome benefits and clearly define and articulate the value they add to the healthcare system.
To read more, click the link below.
Gene therapy competitive dynamics: Winner takes all?
This article was originally published in Cell & Gene. It has also been published in Cell & Gene‘s sister publication, OutSourced Pharama. With many gene...